Receptor News and Research

RSS

New trial demonstrates efficacy of tirzepatide in children and adolescents with type 2 diabetes

New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10-17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both.

18 Sep 2025

Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

In a phase 3 trial, once-daily oral orforglipron induced significant, dose-dependent weight loss over 72 weeks in adults with obesity but no diabetes. It also improved multiple cardiometabolic markers with a safety profile similar to other GLP-1 receptor agonists.

18 Sep 2025

Investigational drug reduces hot flashes and night sweats for post-menopausal women

The investigational drug elinzanetant significantly reduces hot flashes and night sweats for post-menopausal women, a large, international clinical trial has found.

18 Sep 2025

New molecule offers a more targeted and potent immunotherapy

A newly developed molecule brings together two powerful immunotherapy strategies in one treatment. Researchers at the University of Basel and University Hospital Basel, Switzerland, have demonstrated that this fusion protein can both block the "do not attack" signal used by cancer cells and selectively activate tumor-fighting immune cells. This dual action could pave the way for more effective cancer therapies with fewer side effects.

18 Sep 2025

Scientists unveil new obesity drug that reprograms fat and energy use

Details of a new drug that aims to treat the underlying causes of obesity are being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September).

18 Sep 2025

GLP-1RAs linked to lower risk of mortality and cardiovascular events in psoriasis patients

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% lower risk of major cardiovascular events compared to those taking other diabetes or weight-loss medications, new research has shown.

17 Sep 2025

Long COVID linked to heavier periods and symptom flare-ups during menstruation

Researchers found that long COVID is linked to heavier, longer, and more irregular bleeding without disrupting ovulation. Symptom severity also peaks around menstruation, likely driven by hormonal and immune changes.

17 Sep 2025

A new tool in the fight against obesity: Orforglipron's substantial weight loss results

New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15-19) and simultaneously published in NEJM shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substantial weight loss in people living with obesity that do not have type 2 diabetes.

17 Sep 2025

GLP-1 drugs found to protect against diabetic retinopathy

GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss, suggests new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) and published in the journal Pharmaceutics.

17 Sep 2025

The 15th AACR cancer progress report highlights scientific advances

The American Association for Cancer Research (AACR) released the 15th edition of its annual Cancer Progress Report. A cornerstone of the AACR's educational and advocacy efforts, this comprehensive report provides the latest statistics on cancer incidence, mortality, and survivorship and highlights how federal investments in basic, translational, and clinical cancer research and cancer-related population sciences have led to impressive scientific advances that are improving health and saving lives.

17 Sep 2025

The mind-gut connection: How emotional eating affects GLP-1 drug success

GLP-1 receptor agonists like Ozempic can be a lifeline for people with diabetes - helping stabilize blood glucose and lose weight which contributes to diabetes complications. But not everyone benefits equally.

17 Sep 2025

Exercise found to reduce artery hardening after weight loss in adults with obesity

Maintaining weight loss with regular exercise rather than the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide, a drug used to treat type 2 diabetes and obesity, seems to reduce atherosclerosis development in adults with obesity-a leading underlying cause of cardiovascular disease.

17 Sep 2025

Triple negative breast cancer exploits lymph node niches to block immune defense

In almost all solid tumors - i.e. cancers with a solid tissue structure - the detection of tumor cells in the lymph nodes is considered a decisive marker for the progression of the disease.

16 Sep 2025

Higher-dose semaglutide helps people lose nearly 19% of body weight

The STEP UP trial reveals semaglutide 7.2 mg significantly reduces weight compared to 2.4 mg, though it raises questions about gastrointestinal side effects.

16 Sep 2025

AlphaFold3 predicts bitter taste receptor structures with greater accuracy

Receptor proteins, expressed on the cell surface or within the cell, bind to different signaling molecules, known as ligands, initiating cellular responses.

16 Sep 2025

Cleveland Clinic study shows lasting benefits of weight-loss surgery over GLP-1 medicines

A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo weight-loss surgery live longer and face fewer serious health problems compared with those treated with GLP-1 receptor agonist medicines alone.

16 Sep 2025

Individuals taking semaglutide for weight loss experience less food noise than before

New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) shows that individuals who are taking semaglutide for weight loss experience less food noise than before.

16 Sep 2025

Study reveals how centenarians preserve youthful immune defenses

Researchers mapped immune cells from centenarians, their offspring, and younger controls across three cohorts using multi-omics single-cell profiling. They found that centenarians retain leaner helper pools but have enhanced cytotoxic and NK cell programs, along with reinforced NK–T communication networks.

15 Sep 2025

SwRI and UT San Antonio advance biosensor coating to streamline production of immunotherapies

Southwest Research Institute (SwRI) and The University of Texas at San Antonio (UT San Antonio) are advancing a smart biosensor coating to streamline the production of immunotherapies for cancer treatments.

15 Sep 2025

Study: Half of adults without diabetes taking weight-loss drug discontinue treatment within a year

The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at helping individuals lose weight.

15 Sep 2025

Receptor News and Research

New trial demonstrates efficacy of tirzepatide in children and adolescents with type 2 diabetes

Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

Investigational drug reduces hot flashes and night sweats for post-menopausal women

New molecule offers a more targeted and potent immunotherapy

Scientists unveil new obesity drug that reprograms fat and energy use

GLP-1RAs linked to lower risk of mortality and cardiovascular events in psoriasis patients

Long COVID linked to heavier periods and symptom flare-ups during menstruation

A new tool in the fight against obesity: Orforglipron's substantial weight loss results

GLP-1 drugs found to protect against diabetic retinopathy

The 15th AACR cancer progress report highlights scientific advances

The mind-gut connection: How emotional eating affects GLP-1 drug success

Exercise found to reduce artery hardening after weight loss in adults with obesity

Triple negative breast cancer exploits lymph node niches to block immune defense

Higher-dose semaglutide helps people lose nearly 19% of body weight

AlphaFold3 predicts bitter taste receptor structures with greater accuracy

Cleveland Clinic study shows lasting benefits of weight-loss surgery over GLP-1 medicines

Individuals taking semaglutide for weight loss experience less food noise than before

Study reveals how centenarians preserve youthful immune defenses

SwRI and UT San Antonio advance biosensor coating to streamline production of immunotherapies

Study: Half of adults without diabetes taking weight-loss drug discontinue treatment within a year

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News